ADC Therapeutics SA (ADCT) stock forecast · rev $40.1M
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
This ADCT forecast page states what the cached financials imply — not a price target and not a guarantee. ADC Therapeutics SA outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported ADCT revenue for 2026-06-30 was $40.1M. Net income was -$49.5M. Revenue was up 92.3% from 2026-03-31 to 2026-06-30. ADCT currently screens at market cap $141.2M.
The near-term path: Revenue was up 92.3% from 2026-03-31 to 2026-06-30. A forecast that ignores that change is just a story.
ADCT currently screens at market cap $141.2M. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next ADCT 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the ADCT stock page.
Not investment advice.